Q2 2024 Earnings Forecast for Aptevo Therapeutics Inc. (NASDAQ:APVO) Issued By Roth Capital

Aptevo Therapeutics Inc. (NASDAQ:APVO) – Equities research analysts at Roth Capital dropped their Q2 2024 earnings per share (EPS) estimates for shares of Aptevo Therapeutics in a research note issued on Wednesday, May 8th. Roth Capital analyst J. Aschoff now expects that the biotechnology company will post earnings of ($1.93) per share for the quarter, down from their prior estimate of ($1.89). The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($8.86) per share. Roth Capital also issued estimates for Aptevo Therapeutics’ Q3 2024 earnings at ($1.71) EPS, Q4 2024 earnings at ($1.70) EPS, FY2024 earnings at ($8.86) EPS, FY2025 earnings at ($5.77) EPS, FY2026 earnings at ($3.26) EPS, FY2027 earnings at $1.90 EPS and FY2028 earnings at $3.22 EPS.

Separately, StockNews.com assumed coverage on shares of Aptevo Therapeutics in a report on Thursday, April 18th. They issued a “sell” rating on the stock.

Aptevo Therapeutics Stock Performance

Shares of NASDAQ APVO opened at $0.89 on Monday. Aptevo Therapeutics has a 52 week low of $0.67 and a 52 week high of $80.96. The business has a 50-day simple moving average of $2.94 and a two-hundred day simple moving average of $6.23.

Institutional Investors Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC bought a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,235,000 shares of the biotechnology company’s stock, valued at approximately $408,000. Armistice Capital LLC owned about 10.72% of Aptevo Therapeutics as of its most recent SEC filing. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.